four pages)------------------------------------------------ 6 Other Biographical Sketch-- (Not to exceed four pages for each -- (See instructions)------------------------------------------------------ 9 Resources-------------------------------------------------------------------------------------------------------------------------------------------------------- 16 Research Plan 18 A.
Specific Aims ------------------------------------------------------------------------------------------------------------------------------------ 18 B. Background and Significance-------------------------------------------------------------------------------------------------------------- 19 C. Preliminary Studies/Progress Report/ (Items A-D: not to exceed 25 pages*) 22 Phase I Progress Report (SBIR/STTR Phase II ONLY) *SBIR/STTR Phase I: Items A-D limited to 15 pages. D. Research Design and Methods------------------------------------------------------------------------------------------------------------ 33 E. Human Subjects-------------------------------------------------------------------------------------------------------------------------------- Protection of Human Subjects (Required if Item 4 on the Face Page is marked """"""""Yes"""""""") Inclusion of Women (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")---------------------------------------------------- Inclusion of Minorities (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")-------------------------------------------------- Inclusion of Children (Required if Item 4 on the Face Page is marked """"""""Yes"""""""")---------------------------------------------------- Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked """"""""yes"""""""" and a Phase I, II, or III clinical trial is proposed) F. Vertebrate Animals---------------------------------------------------------------------------------------------------------------------------- 43 G. Literature---------------------------------------------------------------------------------------------------------------------------------------- 44 H. Consortium/Contractual Arrangements-------------------------------------------------------------------------------------------------- I. Letters of Support (e.g., Consultants)------------------------------------------------------------------------------------------------------ 50 J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY)------------------------------------------------------ Checklist---------------------------------------------------------------------------------------------------------------------------------------------------------- 54 Appendix (Five collated sets: No page numbering necessary for Appendix.) Check if Appendix is Appendices NOT PERMITTED for Phase I SBIR/STTR unless specifically solicited. Included Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev. 05/01) Page 4

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Liu, Lijuan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Tontonoz, Peter; Wu, Xiaohui; Jones, Marius et al. (2017) Long Noncoding RNA Facilitated Gene Therapy Reduces Atherosclerosis in a Murine Model of Familial Hypercholesterolemia. Circulation 136:776-778
Gao, Jie; Marosi, Mate; Choi, Jinkuk et al. (2017) The E3 ubiquitin ligase IDOL regulates synaptic ApoER2 levels and is important for plasticity and learning. Elife 6:
Sallam, Tamer; Jones, Marius C; Gilliland, Thomas et al. (2016) Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature 534:124-8
Ito, Ayaka; Hong, Cynthia; Oka, Kazuhiro et al. (2016) Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease. Immunity 45:1311-1326
Tian, Xiao Yu; Ganeshan, Kirthana; Hong, Cynthia et al. (2016) Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance. Cell Metab 23:165-78
Lee, Stephen D; Tontonoz, Peter (2015) Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242:29-36
Warrier, Manya; Shih, Diana M; Burrows, Amy C et al. (2015) The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep :
Ito, Ayaka; Hong, Cynthia; Rong, Xin et al. (2015) LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. Elife 4:e08009
Choi, Jinkuk; Gao, Jie; Kim, Jaekwang et al. (2015) The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A? amyloidosis. Sci Transl Med 7:314ra184
Calkin, Anna C; Lee, Stephen D; Kim, Jason et al. (2014) Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice. Circ Res 115:442-9

Showing the most recent 10 out of 61 publications